by DealForma Analysts | Mar 9, 2023 | Deal of the Month
February 2023 Top Biopharma Deal: Axsome – Pharmanovia for EDS drug Sunosi February 2023 Top Biopharma Deal Upfront Axsome development and commercialization deal with Pharmanovia for Sunosi Announced: February 22, 2023 Total Deal Value: $167M Upfront Cash: $66M...
by DealForma Analysts | Feb 2, 2023 | Deal of the Month
January 2023 Top Biopharma Deal: Hutchmed – Takeda for cancer drug fruquintinib January 2023 Top Biopharma Deal Upfront Hutchmed development and commercialization deal with Takeda for fruquintinib Announced: January 23, 2023 Total Deal Value: $1,130M Upfront...
by DealForma Analysts | Jan 9, 2023 | Deal of the Month
December 2022 Top Biopharma Deal: Akeso – Summit for Cancer Drug Ivonescimab December 2022 Top Biopharma Deal Upfront Akeso development and commercialization deal with Summit for ivonescimab Announced: December 5, 2022 Total Deal Value: $5,000M Upfront Cash:...
by DealForma Analysts | Dec 9, 2022 | Deal of the Month
November 2022 Top Biopharma Deal: POINT – Lantheus for cancer drugs PNT2002 and PNT2003 November 2022 Top Biopharma Deal Upfront POINT development and commercialization deal with Lantheus for PNT2002 and PNT2003 Announced: November 11, 2022 Total Deal...
by DealForma Analysts | Nov 4, 2022 | Deal of the Month
October 2022 Top Biopharma Deal: MacroGenics – Gilead for blood cancer drug MGD024 October 2022 Top Biopharma Deal Upfront MacroGenics research partnership with Gilead with an option to license MGD024 Announced: October 17, 2022 Total Deal Value: $1,760M Upfront...
by DealForma Analysts | Oct 3, 2022 | Deal of the Month
Deal of the Month September 2022 Top Biopharma Deal: SpringWorks – GSK for Nirogacestat in combination with Blenrep September 2022 Top Biopharma Deal Upfront SpringWorks development and commercialization deal expansion with GSK for Nirogacestat in combination...
by DealForma Analysts | Sep 2, 2022 | Deal of the Month
Deal of the Month August 2022 Top Biopharma Deal: Sanofi – Innovent for Cancer Drugs SAR408701 and SAR444245 August 2022 Top Biopharma Deal Upfront Sanofi development and commercialization deal with Innovent for SAR408701 and SAR444245 Announced: August 24, 2022...
by DealForma Analysts | Aug 22, 2022 | Deal of the Month
Deal of the Month July 2022 Top Biopharma Deal: Orion – MSD for Prostate Cancer Drug ODM-208 July 2022 Top Biopharma Deal Upfront Orion co-development and co-commercialization deal with MSD for ODM-208 Announced: July 13, 2022 Total Deal Value: $290M +...
by DealForma Analysts | Aug 22, 2022 | Deal of the Month
Deal of the Month June 2022 Top Biopharma Deal: Sanofi – Regeneron Pharmaceuticals for Cancer/Inflammation drug Libayo June 2022 Top Biopharma Deal Upfront Sanofi development and commercialization deal with Regeneron for Libtayo (Amended Agreement) Announced:...
by DealForma Analysts | Jun 10, 2022 | Deal of the Month
Deal of the Month May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation May 2022 Top Biopharma Deal Upfront Dragonfly Therapeutics development and commercialization deal with Gilead Sciences for solid...
